PE20190372A1 - Comprimidos de disgregacion oral - Google Patents

Comprimidos de disgregacion oral

Info

Publication number
PE20190372A1
PE20190372A1 PE2018002028A PE2018002028A PE20190372A1 PE 20190372 A1 PE20190372 A1 PE 20190372A1 PE 2018002028 A PE2018002028 A PE 2018002028A PE 2018002028 A PE2018002028 A PE 2018002028A PE 20190372 A1 PE20190372 A1 PE 20190372A1
Authority
PE
Peru
Prior art keywords
approximately
compound
total weight
called
patients
Prior art date
Application number
PE2018002028A
Other languages
English (en)
Inventor
Husban Farhan Abdel Karim Mohammad Al
Lars Håkan Christer Glad
Jenny Malin Christina Hallstein
Andrea Jane Moir
Michael Peter Thompson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58640851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190372(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20190372A1 publication Critical patent/PE20190372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a comprimidos de disgregacion oral, que contiene un compuesto de formula I: Este compuesto se denomina de forma convencional (1S, 2S, 3R, 5S)-3-[7-{[(1R, 2S)-2-(3, 4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3H-[1, 2, 3]-triazolo-[4, 5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1, 2-diol (tambien se denomina ticagrelor); formando parte del comprimido (preferentemente en una cantidad entre 12%-17% aproximadamente del peso total) junto a un excipiente disgregante (puede ser una unica sustancia como crospovidona, croscarmelosa sodica, celulosa microcristalina, entre otros, o una mezcla de sustancias denominada premezcla de excipiente disgregante, contiendo varias de estas al menos un relleno de tipo carbohidrato y al menos un disgregante) en cantidad suficiente (si es una premezcla, debe estar presente en una cantidad entre 50%-80% aproximadamente), pudiendo anadirse un agente apelmazante (preferible si el proceso comprende un paso de granulacion, comprende entre 0.5%-1% del peso total), uno o mas lubricantes (comprende entre 1%-3% del peso total), conservantes, estabilizantes y/o antioxidantes, teniendo el comprimido una dureza entre 50 N-150 N aproximadamente y un tiempo de disgregacion menor a 3 minutos (preferiblemente menor a 60 segundos). Tambien se refiere a procesos de fabricacion, metodos de tratamiento y prevencion, y envases de tipo blister. La presente invencion es util para el tratamiento o prevencion de episodios aterotromboticos en pacientes con una enfermedad cardiovascular, y de la trombosis del stent, asi como para pacientes con problemas de disfagia que necesiten este compuesto.
PE2018002028A 2016-04-21 2017-04-20 Comprimidos de disgregacion oral PE20190372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662325584P 2016-04-21 2016-04-21

Publications (1)

Publication Number Publication Date
PE20190372A1 true PE20190372A1 (es) 2019-03-08

Family

ID=58640851

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002028A PE20190372A1 (es) 2016-04-21 2017-04-20 Comprimidos de disgregacion oral

Country Status (16)

Country Link
US (1) US10729655B2 (es)
EP (1) EP3445338A1 (es)
JP (2) JP6960941B2 (es)
KR (2) KR102392347B1 (es)
CN (3) CN107595789B (es)
AU (2) AU2017253367B2 (es)
BR (1) BR112018071440A2 (es)
CO (1) CO2018012431A2 (es)
EA (1) EA201892150A1 (es)
HK (2) HK1248562A1 (es)
IL (1) IL262312B (es)
MA (1) MA44720A (es)
PE (1) PE20190372A1 (es)
PH (1) PH12018502226A1 (es)
SG (2) SG10202107682QA (es)
WO (1) WO2017182589A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法
CN109700773B (zh) * 2019-03-01 2021-03-16 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛制剂组合物及其制备方法
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
US20220387328A1 (en) 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
CA3232273A1 (en) * 2021-10-04 2023-04-13 Nava Zisapel Methods and products for treating subjects with autism spectrum disorders
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
CN116370423A (zh) * 2023-02-28 2023-07-04 天津力生制药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
ATE333269T1 (de) * 2001-05-10 2006-08-15 Astellas Pharma Inc In der mundhöhle schnell zerfallende tabletten und prozess zu deren herstellung
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CN2717851Y (zh) * 2004-05-14 2005-08-17 重庆康刻尔制药有限公司 一种药品包装板
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
FR2968992B1 (fr) 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
US20130160408A1 (en) 2011-12-22 2013-06-27 Gregor N. Neff Blister Pack and Method
JP5956475B2 (ja) 2012-02-03 2016-07-27 旭化成株式会社 苦味マスク顆粒含有口腔内崩壊錠
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
EA201691582A1 (ru) * 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты

Also Published As

Publication number Publication date
KR102392347B1 (ko) 2022-05-02
AU2020201930A1 (en) 2020-04-09
CN107595789B (zh) 2021-01-15
IL262312A (en) 2018-11-29
CN107595790B (zh) 2021-01-12
AU2017253367B2 (en) 2020-04-16
CN107595790A (zh) 2018-01-19
AU2020201930B2 (en) 2020-10-29
CO2018012431A2 (es) 2018-11-30
HK1249732A1 (zh) 2018-11-09
WO2017182589A1 (en) 2017-10-26
CN107530288A (zh) 2018-01-02
KR20180132147A (ko) 2018-12-11
JP2019516674A (ja) 2019-06-20
IL262312B (en) 2022-08-01
EA201892150A1 (ru) 2019-05-31
EP3445338A1 (en) 2019-02-27
JP6960941B2 (ja) 2021-11-05
CN107595789A (zh) 2018-01-19
WO2017182589A9 (en) 2018-04-19
CN107530288B (zh) 2022-01-25
KR102488486B1 (ko) 2023-01-12
MA44720A (fr) 2019-02-27
HK1248562A1 (zh) 2018-10-19
JP2022009050A (ja) 2022-01-14
US20190117577A1 (en) 2019-04-25
PH12018502226A1 (en) 2019-07-29
AU2017253367A1 (en) 2018-11-08
SG10202107682QA (en) 2021-08-30
SG11201808996SA (en) 2018-11-29
KR20220054907A (ko) 2022-05-03
US10729655B2 (en) 2020-08-04
JP7254871B2 (ja) 2023-04-10
BR112018071440A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
PE20190372A1 (es) Comprimidos de disgregacion oral
AR118108A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
PE20170195A1 (es) Composicion para tratar diabetes, que contiene un conjugado de analogo de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada
MX2007010856A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
AR087205A1 (es) Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas
AR107391A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
MX351232B (es) Inhibidor de dpp-iv combinado con otro agente antidiabetico, tabletas que comprenden tales formulaciones, su uso y procedimiento para su preparacion.
AR089805A1 (es) FORMULACION SECA EN POLVO QUE COMPRENDE UNA CORTICOESTEROIDE Y UN b-ADRENERGICO PARA ADMINISTRAR POR INHALACION
MX2017008161A (es) Pirazolpiridinaminas.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12020500134A1 (en) Dihydrooxadiazinones
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
WO2015155711A4 (en) Immunosuppressant formulation
MY174005A (en) Swallowable n-acetylcysteine tablets
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
MX362485B (es) Nuevos inhibidores de rock.
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
PH12016502540A1 (en) Pharmaceutical dosage forms
DOP2016000078A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
HRPK20120437B3 (hr) Obložena tableta koja sadrži imatinib mesilat, naäśin njezine proizvodnje i primjena
PE20191491A1 (es) Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla